Ying-Tsun Chen

Ying-Tsun Chen

Auto-generated profile, based on publicly available information

Ying-Tsun Chen

Department of Pediatrics, Columbia University, New York, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
AUAndreacarola Urso
Andreacarola Urso
IMIan Monk
Ian Monk
YCYing-Tsun Cheng
Ying-Tsun Cheng
CPCamilla Predella
Camilla Predella
Tania Wong Fok LungTania Wong Fok Lung
Tania Wong Fok Lung
APAlice Prince
Alice Prince
Staphylococcus aureus is a pulmonary pathogen associated with substantial human morbidity and mortality. As vaccines targeting virulence determinants have failed to be protective in humans, other factors are likely involved in pathogenesis. Here we analysed transcriptomic responses of human clinical isolates of S. aureus from initial and chronic infections. We observed upregulated collagenase and proline transporter gene expression in chronic infection isolates. Metabolomics of bronchiolar lavage fluid and fibroblast infection, growth assays and analysis of bacterial mutant strains showed that airway fibroblasts produce collagen during S. aureus infection. Host-adapted bacteria upregulate collagenase, which degrades collagen and releases proline. S. aureus then imports proline, which fuels oxidative metabolism via the tricarboxylic acid cycle. Proline metabolism provides host-adapted S. aureus with a metabolic benefit enabling out-competition of non-adapted strains. These data suggest that clinical settings characterized by airway repair processes and fibrosis provide a milieu that promotes S. aureus adaptation and supports infection.

19 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYing-Tsun Chen
Ying-Tsun Chen
GLGaurav Kumar Lohia
Gaurav Kumar Lohia
SCSamantha Chen
Samantha Chen
ZLZihua Liu
Zihua Liu
Tania Wong Fok LungTania Wong Fok Lung
Tania Wong Fok Lung
SRSebastián A. Riquelme
Sebastián A. Riquelme
Disease tolerance mitigates organ damage from non-resolving inflammation during persistent infections, yet its underlying mechanisms remain unclear. Here we show, in a Pseudomonas aeruginosa pneumonia mouse model, that disease tolerance depends on the mitochondrial metabolite itaconate, which mediates cooperative host-pathogen interactions. In P. aeruginosa, itaconate modifies key cysteine residues in TCA cycle enzymes critical for succinate metabolism, inducing bioenergetic stress and promoting the formation biofilms that are less immunostimulatory and allow the bacteria to integrate into the local microbiome. Itaconate incorporates into the central metabolism of the biofilm, driving exopolysaccharide production—particularly alginate—which amplifies airway itaconate signaling. This itaconate-alginate interplay limits host immunopathology by enabling pulmonary glutamine assimilation, activating glutaminolysis, and thereby restrain detrimental inflammation caused by the inflammasome. Clinical sample analysis reveals that P. aeruginosa adapts to this metabolic environment through compensatory mutations in the anti-sigma-factor mucA, which restore the succinate-driven bioenergetics and disrupt the metabolic synchrony essential for sustaining disease tolerance.

1 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYing-Tsun Chen
Ying-Tsun Chen
ZLZihua Liu
Zihua Liu
DFDario Fucich
Dario Fucich
SGStefano G. Giulieri
Stefano G. Giulieri
ZLZhe Liu
Zhe Liu
Tania Wong Fok LungTania Wong Fok Lung
Tania Wong Fok Lung
Staphylococcus aureus is a leading cause of healthcare-associated pneumonia, contributing significantly to morbidity and mortality worldwide. As a ubiquitous colonizer of the upper respiratory tract, S. aureus must undergo substantial metabolic adaptation to achieve persistent infection in the distinctive microenvironment of the lung. We observed that fumC, which encodes the enzyme that converts fumarate to malate, is highly conserved with low mutation rates in S. aureus isolates from chronic lung infections. Fumarate, a pro-inflammatory metabolite produced by macrophages during infection, is regulated by the host fumarate hydratase (FH) to limit inflammation. Here, we demonstrate that fumarate, which accumulates in the chronically infected lung, is detrimental to S. aureus, blocking primary metabolic pathways such as glycolysis and oxidative phosphorylation (OXPHOS). This creates a metabolic bottleneck that drives staphylococcal FH (FumC) activity for airway adaptation. FumC not only degrades fumarate but also directs its utilization into critical pathways including the tricarboxylic acid (TCA) cycle, gluconeogenesis and hexosamine synthesis to maintain metabolic fitness and form a protective biofilm. Itaconate, another abundant immunometabolite in the infected airway enhances FumC activity, in synergy with fumarate. In a mouse model of pneumonia, a ΔfumC mutant displays significant attenuation compared to its parent and complemented strains, particularly in fumarate- and itaconate-replete conditions. Our findings underscore the pivotal role of immunometabolites in promoting S. aureus pulmonary adaptation.

13 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAyesha Z. Beg
Ayesha Z. Beg
ZLZihua Liu
Zihua Liu
YCYing-Tsun Chen
Ying-Tsun Chen
ATAbsar Talat
Absar Talat
GGGriffin Gowdy
Griffin Gowdy
APAlice Prince
Alice Prince
Inhaled opportunistic pathogens such as Pseudomonas aeruginosa actively modify gene expression to meet the challenges of a new environment. In the infected airway the bacteria must respond to the immunometabolite itaconate, which is abundantly produced by macrophages and has anti-inflammatory and anti-oxidant functions that protect the host from airway damage and causes toxicity to bacteria. As a dicarboxylate that targets cysteine residues, itaconate can modify both bacterial and host proteins often altering metabolic activity. We demonstrate that itaconate promotes a global metabolic response in P. aeruginosa by enhancing the activity of the major alternative transcription factor RpoN. Itaconate is actively transported into the bacteria, induces σ54 rpoN expression and covalently binds cysteine residues 218 and 275 on RpoN helping to neutralize its toxicity. The S-itaconated RpoN exhibits a gain of function driving increased glucose catabolism and enhanced utilization of the bioenergetically efficient Entner–Doudoroff pathway. Thus, the accumulation of itaconate in the infected airway promotes the adaptation of P. aeruginosa to the lung by optimizing its metabolic activity and ability to cause pneumonia.

18 October 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
KTK. Tomlinson
K. Tomlinson
YCY. Chen
Y. Chen
AJA. Junker
A. Junker
AUA. Urso
A. Urso
TWT. Wong
T. Wong
SRS. Riquelme
S. Riquelme

22 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
GLGaurav Kumar Lohia
Gaurav Kumar Lohia
YCYing-Tsun Chen
Ying-Tsun Chen
SCSamantha Chen
Samantha Chen
ABAyesha Beg
Ayesha Beg
ETErin Theiller
Erin Theiller
SRSebastián A. Riquelme
Sebastián A. Riquelme
Cystic fibrosis (CF), caused by CFTR mutations, is characterized by progressive pulmonary remodeling, particularly during bacterial infection. This pathological environment, exacerbated by altered epithelial growth, leads to thickened airway walls, inducing permanent narrowing and long-term breathing difficulties. However, what drives this adverse milieu remains unclear. Here, we identify activation of the de novo pathway of pyrimidine synthesis (DNPPS) as a central contributor of CF lung remodeling. In response to impaired mitochondrial bioenergetics, CFTR-mutant epithelial cells engage compensatory DNPPS activity, functionally coupling mitochondrial oxidative metabolism to pyrimidine production and, inadvertently, promoting proliferation. This phenotype is reversible with CFTR modulators and pharmacologic DNPPS inhibitors using clinically established agents. Strikingly, Pseudomonas aeruginosa, the predominant CF pathogen, undergoes convergent pyrimidine adaptation, activating its own DNPPS machinery to amplify biomass and sustain a remodeled niche. Together, these findings define pyrimidine metabolism as a shared host-pathogen axis driving epithelial restructuring and bacterial persistence in the CF lung.